Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer

Fu Tsai Chung, Kang Yun Lee, Yueh Fu Fang, Meng Heng Shieh, Shu Min Lin, Chih Teng Yu, Yun Lun Lo, Ting-Yu Lin, Chih Hsi Kuo, Po Hao Feng, Yung Lun Ni, Han Pin Kuo

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Objectives: Docetaxel and pemetrexed have been validated as therapeutics for previously treated advanced non-small-cell lung cancer (NSCLC), but tolerability is a concern for standard treatment with docetaxel administered once every 3 weeks (tri-weekly 75-mg/m2 schedule). We conducted this retrospective study to compare the efficacy and toxicity of weekly low-dose docetaxel versus tri-weekly pemetrexed for previously treated advanced NSCLC. Methods: Consecutive patients who received low-dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks) or pemetrexed (500 mg/m 2 every 3 weeks) at a single university-affiliated hospital following failure of previous treatment were retrospectively reviewed. Their outcomes and toxicity profiles were determined. Results: 179 patients were included between 2005 and 2008 (docetaxel, n = 79; pemetrexed, n = 100). Both groups had similar hematologic (16.5 vs. 15.0%; p = 0.84) and non-hematologic (20.3 vs. 24%; p = 0.55) toxicities. After controlling for confounding factors, docetaxel remained superior to pemetrexed for progression-free survival (median 4.0 vs. 2.4 months; hazard ratio 0.64; 95% CI 0.47-0.87; p = 0.005) and overall survival (median 15.0 vs.8.5 months; hazard ratio 0.54; 95% CI 0.38-0.77; p

Original languageEnglish
Pages (from-to)147-155
Number of pages9
Issue number2
Publication statusPublished - Apr 2011
Externally publishedYes


  • Advanced non-small-cell lung cancer
  • Docetaxel
  • Pemetrexed

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology


Dive into the research topics of 'Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this